title: Lumpectomy and breast radiotherapy in breast cancer patients with a family history of breast cancer, ovarian cancer, or both.
abstract: This article presents an outcomes review of breast cancer patients identified from the cancer registries of four area hospitals. These patients had family histories of breast cancer, ovarian carcinoma, or both and were treated with conservative surgery and radiation to the involved breast. Patients were as follows: group 1, one first-degree relative ( n = 165, one synchronous bilateral breast cancer); group 2, > or =2 first-degree relatives ( n = 21); group 3, one second-degree relative ( n = 20); and group 4, > or =2 second-degree relatives ( n = 18). The total of patients and breast cancer events was 224 and 225, respectively. Group 5 was a subgroup of 53 patients with a substantial risk (>10%) of a BRCA1 or BRCA2 mutation. After a median follow-up of 3.9 years, 5 patients had local failure (2%), and 5 developed a contralateral breast cancer (2%). There were no significant differences in local failure rates between groups (p = 1.0): group 1, 5 of 166 (3%); group 2, 0 of 21 (0%); group 3, 0 of 20 (0%); and group 4, 0 of 18 (0%). Local failure for group 5 was 2% (1 of 53). Four of 143 patients (3%) with a minimum 3 years of follow-up (median, 5.6 years) had local failure, and 5 (4%) developed a contralateral breast cancer. A univariate analysis was statistically significant for differentiation only (well, 0 of 67; moderately, 1 of 57 [1.8%]; poor, 3 of 26 [11.5%], p = 0.008). Overall survival for groups 1-4 did not differ significantly. Although follow-up has been relatively short, we have not found that breast cancer patients with various degrees of family histories of breast/ovarian carcinoma have had a detrimental outcome when treated with conservative therapy.
authors.affiliation: Rocky Mountain Cancer Centers; Department of Radiation Oncology, Denver, Colorado 80110, USA.
authors.forename: Charles E
authors.initials: CE
authors.lastname: Leonard
authors.forename: Scot
authors.initials: S
authors.lastname: Sedlacek
authors.forename: Howard
authors.initials: H
authors.lastname: Shapiro
authors.forename: Diana
authors.initials: D
authors.lastname: Hey
authors.forename: Xiolan
authors.initials: X
authors.lastname: Liang
authors.forename: Kathryn
authors.initials: K
authors.lastname: Howell
authors.forename: Ben
authors.initials: B
authors.lastname: Vernon
authors.forename: Josie
authors.initials: J
authors.lastname: Ponce
authors.forename: Lynda
authors.initials: L
authors.lastname: Smith
mesh_terms: D000704:Analysis of Variance; D001943:Breast Neoplasms / Q000235:genetics / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006801:Humans; D015412:Mastectomy, Segmental; D009154:Mutation; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000235:genetics; D011336:Probability; D012042:Registries; D015996:Survival Rate; D016896:Treatment Outcome